Trials / Completed
CompletedNCT06190093
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects with Neovascular Age-related Macular Degeneration; NORSE EIGHT
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Outlook Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Conditions
- Neovascular Age-related Macular Degeneration
- Age-Related Macular Degeneration
- Wet Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bevacizumab | 1.25 mg, intravitreal injection |
| BIOLOGICAL | ranibizumab | 0.5mg, intravitreal injection |
Timeline
- Start date
- 2024-01-24
- Primary completion
- 2024-11-07
- Completion
- 2024-12-05
- First posted
- 2024-01-05
- Last updated
- 2025-02-25
Locations
61 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06190093. Inclusion in this directory is not an endorsement.